Biotechnology
Gene editing, cancer biotechnology, regenerative medicine, longevity science and the evidence moving from laboratories into clinical care.
-
A Small Liver Trial Gives Senolytics a Human Test With Clear Limits
A 31-person liver-disease study reports a biopsy signal from senolytic drugs. Its size, short follow-up and adverse events make larger trials essential.
-
Five-Year Brain Organoids Open a Longer Window on Human Cell Development
Brain organoids grown for five years let researchers examine prolonged human development. Their maturity has to be measured, not inferred from survival.
-
Bird Genomes Expand an RNA Route for Inserting Genes Into Human Cells
A new study mined more than 1,100 bird genomes for R2 elements and engineered gene-insertion tools. The results come from cells in the laboratory.
-
A Phase III Lymphoma Result Moves Bispecific Antibodies Into the Frontline Debate
Epcoritamab plus R-CHOP reduced the risk of lymphoma progression or death in a Phase III trial. The full results and regulatory review still lie ahead.
-
Genentech’s Alector Deal Tests the Brain’s Enzyme Delivery Barrier
A new licence centres on getting a recycling enzyme into the brain. The Parkinson’s programme remains preclinical, and the biological rationale is not yet proof of benefit.
-
Ageing Mouse Immune Cells Lose a Scaffold That Helps Organise DNA
A new study links declining SATB1 to altered genome folding in mouse T cells. It offers a mechanism to investigate, without demonstrating human rejuvenation.
-
Rina-S Shows Durable Ovarian Cancer Responses as the Comparative Test Continues
New Phase I/II results show tumour responses in previously treated ovarian cancer. A randomized Phase III study addresses the harder question of benefit against other treatment.
-
Human Stem-Cell Grafts Give Gene Editing a More Personal Test for Muscular Dystrophy
Scientists need dependable ways to test gene correction before human trials. An experimental model asks a crucial question: which version of a protein has returned?
-
A Major Cancer Blood-Test Trial Shows Why Finding More Cancer Is Only the First Test
New NHS-Galleri papers provide detailed results from 142,250 participants. The trial missed its main goal, even as it found signals worth following.
-
An Engineered Virus Shows a Promising but Uneven Signal Against Pancreatic Cancer
A Phase IIb study tested VCN-01 alongside chemotherapy. The new peer-reviewed report shows why its survival signal needs a larger confirming trial.
-
Novartis’s New RNA Deal Aims to Make an Immune Drug Inside the Body
Novartis is licensing an experimental RNA treatment that tells cells to make an immune-targeting protein. The agreement is significant, but the human evidence remains early.
-
The Designer-Baby Debate Is Moving Beyond Gene Editing
A new ethics correspondence argues that embryo editing and selection need joint governance. Polygenic screening already puts prediction, marketing and oversight in conflict.